Clinical Research Papers:

Targeted sequencing of tonsillar and base of tongue cancer and human papillomavirus positive unknown primary of the head and neck reveals prognostic effects of mutated FGFR3

Cinzia Bersani _, Lars Sivars, Linnea Haeggblom, Sebastian DiLorenzo, Michael Mints, Andreas Ährlund-Richter, Nikolaos Tertipis, Eva Munck-Wikland, Anders Näsman, Torbjörn Ramqvist and Tina Dalianis

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:35339-35350. https://doi.org/10.18632/oncotarget.15240

Metrics: PDF 1627 views  |   HTML 2349 views  |   ?  


Cinzia Bersani1, Lars Sivars1, Linnea Haeggblom1, Sebastian DiLorenzo2,3, Michael Mints4,5, Andreas Ährlund-Richter1, Nikolaos Tertipis1, Eva Munck-Wikland6,7, Anders Näsman1, Torbjörn Ramqvist1,* and Tina Dalianis1,*

1 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

2 Department of Medical Sciences, Uppsala University, Uppsala, Sweden

3 National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

4 Department of Medicine, Karolinska Institutet, Stockholm, Sweden

5 Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden

6 Department of Clinical Science and Technology, Karolinska Institutet, Stockholm, Sweden

7 Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Karolinska University Hospital, Stockholm, Sweden

* These authors have contributed equally to this work

Correspondence to:

Cinzia Bersani, email:

Keywords: HPV, tonsillar cancer, base of tongue cancer, cancer of unknown primary of the head and neck region, FGFR3 mutation

Received: December 21, 2016 Accepted: January 24, 2017 Published: February 09, 2017


BACKGROUND: Human papillomavirus positive (HPV+) tonsillar cancer (TSCC), base of tongue cancer (BOTSCC) and unknown primary cancer of the head and neck (HNCUP) have better outcome than corresponding HPV- cancers. To find predictive markers for response to treatment, and correlations and differences in mutated oncogenes and suppressor genes between HPV+ TSCC/BOTSSCC and HPV+ HNCUP and HPV- TSCC/BOTSCC targeted next-generation sequencing was performed of frequently mutated regions in 50 cancer related genes.

PATIENTS AND METHODS: DNA from 348 TSCC/BOTSCC and 20 HNCUP from patients diagnosed 2000-2011, was sequenced by the Ion Proton sequencing platform using the Ion AmpliSeq Cancer Hotspot Panel v2 to identify frequently mutated regions in 50 cancer related genes. Ion Torrent Variant Caller software was used to call variants.

RESULTS: 279 HPV+ TSCC/BOTSCC, 46 HPV- TSCC/BOTSCC and 19 HPV+ HNCUP samples qualified for further analysis. Mutations/tumor were fewer in HPV+ TSCC/BOTSCC and HNCUP, compared to HPV- tumors (0.92 vs. 1.32 vs. 1.68). Differences in mutation frequency of TP53 and PIK3CA were found between HPV+ TSCC/BOTSCC and HNCUP and HPV- TSCC/BOTSCC. In HPV+ TSCC/BOTSCC presence of FGFR3 mutations correlated to worse prognosis. Other correlations to survival within the groups were not disclosed.

CONCLUSIONS: In HPV+ TSCC/BOTSCC mutation of PIK3CA was most frequently observed, while TP53 mutations dominated in HPV- TSCC/BOTSCC. In HPV+ TSCC/BOTSCC and HNCUP, mutations/tumor were similar in frequency and fewer compared to that in HPV- TSCC/BOTSCC. Notably, FGFR3 mutations in HPV+ TSCC/BOTSCC indicated worse prognosis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15240